Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Braconi

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Mediators of Inflammation|May 31, 2014
Amyloidosis, inflammation, and oxidative stress in the heart of an alkaptonuric patientLia Millucci, Lorenzo Ghezzi, Eugenio Paccagnini, et al.
Computers in Biology and Medicine|October 14, 2018
A new integrated and interactive tool applicable to inborn errors of metabolism: Application to alkaptonuriaOttavia Spiga, Vittoria Cicaloni, Andrea Zatkova, et al.
Archives of Biochemistry and Biophysics|January 29, 2022
Homogentisic acid induces autophagy alterations leading to chondroptosis in human chondrocytes: Implications in AlkaptonuriaSilvia Galderisi, Maria Serena Milella, Martina Rossi, et al.
Biochimica Et Biophysica Acta|August 2, 2012
Alkaptonuria is a novel human secondary amyloidogenic diseaseLia Millucci, Adriano Spreafico, Laura Tinti, et al.
Cells|November 26, 2022
Effects of Nitisinone on Oxidative and Inflammatory Markers in Alkaptonuria: Results from SONIA1 and SONIA2 StudiesDaniela Braconi, Michela Geminiani, Eftychia Eirini Psarelli, et al.
Journal of Inherited Metabolic Disease|October 15, 2019
Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuriaLakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
Annals of the Rheumatic Diseases|December 6, 2014
Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatmentLakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
The Lancet. Diabetes & Endocrinology|August 22, 2020
Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trialLakshminarayan R Ranganath, Eftychia Eirini Psarelli, Jean-Baptiste Arnoux, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Mediators of Inflammation|May 31, 2014
Amyloidosis, inflammation, and oxidative stress in the heart of an alkaptonuric patientLia Millucci, Lorenzo Ghezzi, Eugenio Paccagnini, et al.
Computers in Biology and Medicine|October 14, 2018
A new integrated and interactive tool applicable to inborn errors of metabolism: Application to alkaptonuriaOttavia Spiga, Vittoria Cicaloni, Andrea Zatkova, et al.
Archives of Biochemistry and Biophysics|January 29, 2022
Homogentisic acid induces autophagy alterations leading to chondroptosis in human chondrocytes: Implications in AlkaptonuriaSilvia Galderisi, Maria Serena Milella, Martina Rossi, et al.
Biochimica Et Biophysica Acta|August 2, 2012
Alkaptonuria is a novel human secondary amyloidogenic diseaseLia Millucci, Adriano Spreafico, Laura Tinti, et al.
Cells|November 26, 2022
Effects of Nitisinone on Oxidative and Inflammatory Markers in Alkaptonuria: Results from SONIA1 and SONIA2 StudiesDaniela Braconi, Michela Geminiani, Eftychia Eirini Psarelli, et al.
Journal of Inherited Metabolic Disease|October 15, 2019
Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuriaLakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
Annals of the Rheumatic Diseases|December 6, 2014
Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatmentLakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
The Lancet. Diabetes & Endocrinology|August 22, 2020
Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trialLakshminarayan R Ranganath, Eftychia Eirini Psarelli, Jean-Baptiste Arnoux, et al.
Pageof 7